Inventiva (IVA) News Today → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free IVA Stock Alerts $3.35 -0.09 (-2.62%) (As of 05/9/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineInventiva S.A. (NASDAQ:IVA) Short Interest Updatemarketbeat.com - April 28 at 4:36 AMInventiva S.A. ADRwsj.com - April 26 at 9:24 PMHepion ends Phase 2 study for NASH drug due to cash restraintsmsn.com - April 19 at 5:48 PMCanaccord Genuity Group Increases Inventiva (NASDAQ:IVA) Price Target to $20.00marketbeat.com - April 8 at 8:29 AMInventiva S.A. Expected to Earn FY2025 Earnings of ($2.92) Per Share (NASDAQ:IVA)marketbeat.com - April 4 at 9:44 AMInventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-Fglobenewswire.com - April 3 at 4:00 PMHC Wainwright Analysts Increase Earnings Estimates for Inventiva S.A. (NASDAQ:IVA)marketbeat.com - April 3 at 6:46 AMJulianne Moore y Nicholas Galitzine buscan seducir a un rey en “Mary & George”msn.com - April 1 at 5:29 PMBuy Rating Affirmed: Inventiva’s Progress and Promise in Lanifibranor’s Clinical Trialsmarkets.businessinsider.com - April 1 at 5:14 PMInventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - April 1 at 5:14 PMInventiva (NASDAQ:IVA) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - April 1 at 8:30 AMAnalysts Are Bullish on Top Healthcare Stocks: Inventiva (IVA), Palisade Bio (PALI)markets.businessinsider.com - March 28 at 7:37 PMINVENTIVA: Inventiva announces the nomination of Andre Turenne as Directorfinanznachrichten.de - March 28 at 9:36 AMInventiva announces the nomination of Andre Turenne as Directorglobenewswire.com - March 28 at 3:00 AMINVENTIVA: Inventiva reports its 2023 full-year resultsfinanznachrichten.de - March 27 at 7:59 PMInventiva reports its 2023 full-year resultsglobenewswire.com - March 27 at 4:00 PMInventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Resultsglobenewswire.com - March 22 at 4:00 PMPromising Phase 2 Results Bolster Buy Rating for Inventiva’s Lanifibranor in Type 2 Diabetes and MASH Treatmentmarkets.businessinsider.com - March 21 at 6:52 AMInventiva (NASDAQ:IVA) Receives "Buy" Rating from HC Wainwrightmarketbeat.com - March 20 at 8:37 AMInventiva (IVA) to Release Quarterly Earnings on Wednesdaymarketbeat.com - March 20 at 2:32 AMPRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approvalmarkets.businessinsider.com - March 18 at 5:41 PMInventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2Dglobenewswire.com - March 18 at 4:00 PMMadrigal: Accelerated Rezdiffra Approval Puts It In The NASH Leadseekingalpha.com - March 18 at 12:41 PMShares of Madrigal Pharmaceuticals soar on FDA approval for NASH treatmentbizjournals.com - March 14 at 6:45 PMInventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2Dglobenewswire.com - March 13 at 4:00 PMInventiva’s Clinical Progress and Financial Valuation Reinforce Buy Ratingmarkets.businessinsider.com - March 8 at 2:44 PMInventiva’s Buy Rating Affirmed: Swift Management Actions and Strong Safety Profile Signal Promising Outlookmarkets.businessinsider.com - March 8 at 12:40 AMInventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumedglobenewswire.com - March 7 at 4:00 PMInventiva S.A. (NASDAQ:IVA) to Post FY2023 Earnings of ($2.26) Per Share, HC Wainwright Forecastsmarketbeat.com - February 23 at 6:34 AMBuy Rating for Inventiva Despite Temporary Trial Setback: Analyst Sees Isolated Incident and Strong Safety Recordmarkets.businessinsider.com - February 17 at 7:54 PMInventiva halt recruitment for Phase III NASH trial following adverse eventmsn.com - February 16 at 2:03 PMStifel Nicolaus Cuts Inventiva (NASDAQ:IVA) Price Target to $25.00marketbeat.com - February 16 at 10:49 AMInventiva Stock Falls 20% After Pausing Screening, Randomization in Trial Due to Adverse Eventmarketwatch.com - February 16 at 9:03 AMINVENTIVA: Inventiva reports preliminary 2023 fiscal year financial Information and provides an update on its clinical trial NATiV3finanznachrichten.de - February 15 at 6:00 PMInventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3finance.yahoo.com - February 15 at 6:00 PMInventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3globenewswire.com - February 15 at 4:35 PM11 of the Best Investing Books for Beginnersmsn.com - February 6 at 5:47 PMInventiva S.A. (NASDAQ:IVA) Receives Consensus Rating of "Buy" from Brokeragesmarketbeat.com - February 4 at 5:10 AMFDA accepts Adaptimmune BLA for afami-cel, decision expected by Aug. 4msn.com - January 31 at 9:47 PMInventiva SA ADR IVAmorningstar.com - January 31 at 5:48 PMHalf-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreuxmarkets.businessinsider.com - January 24 at 8:07 PMINVENTIVA: Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreuxfinanznachrichten.de - January 24 at 5:07 PMNon-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsightfinance.yahoo.com - January 17 at 5:48 PMINVENTIVA: Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bankfinanznachrichten.de - January 10 at 7:29 PMInventiva (NASDAQ:IVA) Earns "Outperform" Rating from Lifesci Capitalmarketbeat.com - January 9 at 8:31 AMAnalysts Offer Insights on Healthcare Companies: Inventiva (IVA) and Annexon Biosciences (ANNX)markets.businessinsider.com - December 21 at 11:01 PMInventiva (NASDAQ:IVA) Price Target Lowered to $24.00 at HC Wainwrightmarketbeat.com - December 21 at 8:22 AMInventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development programfinance.yahoo.com - December 20 at 7:26 PMInventiva S.A. (NASDAQ:IVA) Sees Large Decline in Short Interestmarketbeat.com - December 17 at 2:56 PMInventiva S.A. (NASDAQ:IVA) Receives Consensus Recommendation of "Buy" from Analystsmarketbeat.com - December 16 at 6:43 AM Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Exposed: 10 CENT Crypto to Explode May 20th? (Ad)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career… Click For My #1 FREE Crypto for 2024 IVA Media Mentions By Week IVA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IVA News Sentiment▼0.000.43▲Average Medical News Sentiment IVA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IVA Articles This Week▼02▲IVA Articles Average Week Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SCPH News Today TELO News Today OGI News Today GLSI News Today ALIM News Today CAPR News Today MCRB News Today GOSS News Today ACRV News Today PRQR News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IVA) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaObama’s Forever Term [exposed]Porter & CompanyThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders348 million Americans lives to END as we know it?The Oxford ClubUrgent Nvidia WarningAltimetryRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
